CompletedPhase 2NCT00309257
Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome
Studying Alport syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Principal Investigator
- Erica Daina, MDMario Negri Institute for Phrmacological Research
- Intervention
- ACE I, ATA II and Statins(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 15-70 years · All sexes
- Timeline
- 2004 – 2009
Study locations (1)
- Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00309257 on ClinicalTrials.govOther trials for Alport syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07211685BAY3401016; Biomarker Study AlportBayer
- ACTIVE NOT RECRUITINGPHASE4NCT06499948Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)Stefan Lujinschi
- ACTIVE NOT RECRUITINGNCT06226896Effects of Dapagliflozin on Progression of Alport SyndromeNanjing University School of Medicine
- RECRUITINGNCT06526741ASF Alport Patient RegistryAlport Syndrome Foundation
- ACTIVE NOT RECRUITINGPHASE2NCT04573920Atrasentan in Patients With Proteinuric Glomerular DiseasesNovartis Pharmaceuticals
- RECRUITINGNCT04947813Genotype-Phenotype Correlations in Patients With Alport SyndromeXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT05927467Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02378805Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeUniversity Hospital Goettingen